title: Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
abstract: T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinical trials. Here, we review and compare the results of the reported clinical trials and discuss the progress and key emerging factors that may play a role in effecting tumor responses. We also discuss the outlook for CAR T-cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies. Many questions remain in the field of CAR T cells directed to hematologic malignancies, but the encouraging response rates pave a wide road for future investigation.
authors.affiliation: Abramson Cancer Center.
authors.forename: Marcela V
authors.initials: MV
authors.lastname: Maus
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
mesh_terms: D000740:Anemia / Q000378:metabolism; D000906:Antibodies / Q000276:immunology; D018941:Antigens, CD19 / Q000276:immunology; D001402:B-Lymphocytes / Q000166:cytology; D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D015614:Histiocytosis; D006801:Humans; D007107:Immune System; D016219:Immunotherapy, Adoptive; D010587:Phagocytosis; D015202:Protein Engineering; D011946:Receptors, Antigen / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology* / Q000378:metabolism
chemical_list: D000906:Antibodies; D018941:Antigens, CD19; D011946:Receptors, Antigen